US Stock MarketDetailed Quotes

AIM AIM ImmunoTech

Watchlist

0.3700
-0.0003-0.08%

Close Jul 22 16:00 ET

0.3699
-0.0001-0.03%

Post 19:57 ET

21.14MMarket Cap-578P/E (TTM)

AIM ImmunoTech Stock Forum

Mafiosa818

Jun 6 14:36

$AIM ImmunoTech(AIM.US)$ 👀

MonkeyGee

Jun 6 14:35

Avian Flu Play

$AIM ImmunoTech(AIM.US)$

AIM ImmunoTech(AIM) 0.4648 +23.62%

Trytosaveabit

Apr 29 08:00

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Jaguar8

Apr 10 07:26

$AIM ImmunoTech(AIM.US)$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...

Trytosaveabit

Mar 25 08:16

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Trytosaveabit

Feb 8 07:52

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 2 MINUTES AGO, 8:50 AM EST VIA GLOBENEWSWIRE

Trytosaveabit

Jan 24 08:14

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE

Trytosaveabit

Jan 10 07:49

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Trytosaveabit

Nov 27, 2023 08:12

News

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Issued Two US Patents Titled 'Compositions for Cancer Therapy and Methods' And 'Methods for Improving Exercise Tolerance in Myalgic Encephalomyelitis Patients'

Trytosaveabit

Nov 21, 2023 11:14

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 12 MINUTES AGO, 12:00 PM EST VIA GLOBENEWSWIRE AIM SHARE No severe adverse events reported to date Topline data expected as early as Q1 2024

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Overall